NEW YORK (GenomeWeb) – Vermillion today said it has received US Food and Drug Administration 510(k) clearance for its Overa ovarian cancer test.

The test is a second-generation version of the company's OVA1 test, and like OVA1 is intended to aid clinicians in assessing whether a pelvic mass slated for surgery is likely malignant or benign. In the case of likely malignant masses, patients can then be passed on for surgery to a gynecologic oncologist, as opposed to having the surgery done by their regular Ob/Gyn.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.